NEWALR&D LTD
Company number 09243410 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£10,266,708
Balance sheet as at 2025-03-31
What it does
Ezrin peptide pharmaceutical product development
The company's own description, from its latest filed accounts.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2014-10-01
- Employees
- 0 (2025 accounts)
- Registered office
- 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ
- Postcode
- WC2H 9JQ
- Capital
- 28 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-03-31
- Next due by
- 2026-12-31
- Financial year end
- 31 March
Confirmation statement
- Last statement dated
- 2025-10-14
- Next due by
- 2026-10-28
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 3 current · 2 resigned
Previous registered addresses 1
| Address | Changed on |
|---|---|
| 10 LANCASTER GROVE BELSIZE PARK, LONDON, LONDON, NW3 4NX | 2015-10-08 |
Among its peers
Top 5%
by shareholders' funds, of 113 similar companies in WC
Among the oldest 25% of its local peers, trading since 2014.
No.3 of the largest research and experimental development on biotechnology companies in London →
Competitors London
-
5. SENTCELL LTD
This company ranks 3 among research and experimental development on biotechnology in London.
The class of 2014
38%
of the 357 companies in this sector incorporated in 2014 are still active today; 59% have since been dissolved.
A fact about the year, not a forecast for this company.